Pinned Tweet
Join a 30-minute morning educational session led by Drs. Myung-Ju Ahn and Natasha Leighl on October 1st at 9 am KST! They’ll explore TROP2-directed ADCs in EGFR-mutated advanced NSCLC after TKI failure, with guidance on patient selection and toxicity management.
ESMO TAT Asia 2025 초록 모집 안내 (~4/29 마감)
ESMO TAT (Targeted Anticancer Therapies) Asia Congress 2025 (7/18~7/20) 홍콩에서 개최됩니다.
[ESMO Targeted Anticancer Therapies Asia Congress 2025 - Submit your abstract] youtu.be/DENYodl8IFw?si=Wr0V…
Byoung Chul Cho, M.D., Ph.D. retweeted
Today, we presented new preclinical #data supporting intracranial activity of NVL-655 at #AACR23. Thank you to our collaborators Dr. Cho @cbcbc1971 and his group at Yonsei University College of Medicine. bit.ly/3opryDI
Byoung Chul Cho, M.D., Ph.D. retweeted
On National Lung Cancer Screening Day, I would like to thank and support the efforts of Byoung Chul Cho @cbcbc1971 & his study -Novel drug for #LungCancer showing promise in early-stage clinical trials @marjoriezettler Learn how @qure_ai is working for the cause. #RSNA22
Byoung Chul Cho, M.D., Ph.D. retweeted
Replying to @cbcbc1971
@cbcbc1971 nicely overviewed antibody-drug conjugates (ADCs), bispecific antibodies. T-DXd, Dato-DXd, HER3-DXd, Teliso-V, Amivantamab, and Tarlatamab, etc. #LCSM #TASLC
Today, we presented new preclinical #data supporting intracranial activity of NVL-655 at #AACR23. Thank you to our collaborators Dr. Cho @cbcbc1971 and his group at Yonsei University College of Medicine.
Byoung Chul Cho, M.D., Ph.D. retweeted
Looking forward to seeing you at #WCLC2021!! If anyone else is interested in Antibody–Drug Conjugates in #lungcancer, Please come to the education session ES04 at @WCLC2021 on Sep 10.
Looking forward to seeing you at #WCLC2021!! If anyone else is interested in Antibody–Drug Conjugates in #lungcancer, Please come to the education session ES04 at @WCLC2021 on Sep 10.


















